HCV Advocate Newsletter: 2017
This site includes links to files you can view online or print. To download and print information, you will need the latest version of Adobe Acrobat Reader. Download it free.
Reports from 2017 The Liver Meeting
- The Liver Meeting by Alan Franciscus:
- HCV screening rates among baby boomers
- A study on a marker that could lead to a condition called multiple myeloma
- Part B of the Co-Star study abut reinfections rates among people who inject drugs
- Identification of new subtypes and a new HCV genotype
- Adherence rates to treatment and the effect of being cured of hepatitis C
- Long-term follow-up on people with no or minimal fibrosis who were cured of hepatitis C – what is their disease progression and liver cancer rates?
- The Liver Meeting by Lucinda Porter:
- Curing hepatitis C (HCV) and reducing liver cancer
- Curing HCV and improvements in quality of life among people with hepatitis C
- Increase in liver cancer in patients without cirrhosis
- Fatty Liver and heart disease
- Men who have sex with men and acute HCV
- Mislabeling of herbs and dietary supplements
- Parkinson’s disease and hepatitis C medications
- HCV treatment and the risk of heart disease
- HCV positive livers transplanted to HCV negative recipients
Under the Umbrella by Matthew Zielske – One More Shot! Matthew delves into his own recovery and how we can change a person’s life by realizing their potential.
We have updated and added the following HCSP Fact Sheets:
Please read this entire note – important information about our drug pipeline and The Liver meeting!
- Last month Merck canceled their drug development program. This was the last hepatitis C medication that was in drug development. As a result, we will be discontinuing our HCV Advocate Monthly Pipeline Update in our newsletter and on the Website. This is actually good news because there are now medications that have cure rates up to 100%.
- American Association for the Study of Liver Disease (AASLD) – The Liver Meeting is not covered in this month’s HCV Advocate newsletter. Instead, we will provide coverage in the December 2017 HCV Advocate newsletter. I will continue to post news articles in our blog.
In this month’s HCV Advocate newsletter the following articles are available:
- SnapShots by Alan Franciscus—this month’s SnapShots I write about successful retreatment of people who developed NS5A resistance.
- HealthWise by Lucinda K. Porter, RN – Living with Hepatitis C and Stress. Lucinda discusses why we shouldn’t jump to our own conclusions about health problems and instead seek medical advice.
- Hepatitis C and Liver Cancer by Alan Franciscus – I discuss the basics of liver cancer and hepatitis C and what can be done to eliminate or reduce the risk of developing liver cancer.
- Under the Umbrella by Matthew Zielske –The Challenge of Compromise on the Path to Zero. Matthew writes about the opiate crisis, the training workshops and working together for a common goal of eliminating the opioid crisis and hepatitis C.
- What’s Up!
- A new fact sheet – Hepatitis C in Children – read our comprehensive fact sheet on children and HCV, and the many facets of having a chronic disease.
- Updated fact sheet: How to Tell Children They Have Hepatitis C – this is a hard decision to tell a child they have hepatitis C but it is an important one. The fact sheet has really good information to help guide parents, caregivers, and loved ones.
Fall is here and The Liver Meeting is right around the corner! But first, we have a spectacular October HCV Advocate newsletter to help you on your personal healthcare journey, your outreach efforts or just for your reading pleasure.
This month’s HCV Advocate newsletter includes:
- SnapShots by Alan Franciscus – This month’s SnapShots features three studies devoted to understanding the relationship between being cured with treatment of direct-acting antiviral medications (DAAs) and liver cancer. While these studies don’t settle the question 100% they come pretty darn close!
- HealthWise by Lucinda K. Porter – Hepatitis C and Health Literacy. Lucinda discusses the need to inform individuals about their health and why we need to do more to educate others about hepatitis C and get people to be tested. It’s about stepping up our efforts.
- Under The Umbrella by Matthew Zielske—Hepatitis C Statistics and Information: The Elephant in the Room. In his article, Matthew discusses how statistics can help and harm when we are educating our communities.
- What’s Up! We are continuing our partnership with PACKHEALTH to offer a limited number of coaching programs for people with hepatitis C – whether you need help accessing treatment, affording treatment, or simply staying on track. Check out What’s Up!, for more information and how to enroll in this free program. Don’t forget this is a short-term program so don’t miss out.
Note: Our blog specials for October will feature articles about extrahepatic manifestations (EH) of hepatitis C. The blog articles will be single topic overviews of various EHs to educate our audience to help people identify and advocate for treatment of these extrahepatic manifestations. You can see our blog here and signup for the eblast for that site here.
Notice discrepancies, errors or have questions about the newsletter? Do you have topics you would like covered? Drop me a line by filling in our Contact form and using the subject “Feedback”.
We have an exciting issue this month that features a bunch of information that I hope will enrich your personal education and your outreach efforts plus help in your treatment journey.
- What’s Up! This month we are partnering with Packhealth to offer a limited number of coaching programs for people with hepatitis C – whether you need help accessing treatment, affording treatment, or simply staying on track. Check out What’s Up! for more information and how to enroll in this free program.
- Hepatitis C in Prisons by Alan Franciscus – I discuss what we know and don’t know about the state of hepatitis C in jails and prisons including the prevalence, barriers to treatment and some innovative ideas to solve the dilemma of testing and treatment in prisons.
- HCV Drugs by Alan Franciscus AbbVie’s Mavyret Approved – Read about the approval and why this medication may be a game-changer – hint: the price and effectiveness!
- SnapShots by Alan Franciscus – Read about the ethnic and racial disparities in hepatitis C disease progression before and after being cured – important information that should help encourage people to be treated and hopefully improve access to treatment.
- HealthWise by Lucinda K. Porter – Hepatitis C Is Threatening Our Youth – The opioid epidemic is threatening our youth and young adults. But it’s not just drugs! Learn about how to protect yourself and your children in this informative article.
- Under The Umbrella by Matthew Zielske – Education in the HCV Treatment Cascade. In this month’s column Matthew discusses the importance of education as a first step even when other services can’t be offered. This is a comment or question that we constantly receive. See how Matthew answers this important question.
In this month’s Eblast we have a lot of information to pass on to you. At the top of the list is that a new combination of hepatitis C medications was approved by the Food and Drug Administration (FDA) to re-treat people who have not been cured with a previous course of certain direct-acting antiviral medications. You can read about it in this month’s HCV Advocate newsletter.
This month’s newsletter includes:
- HCV SnapShots by Alan Franciscus includes HCV Drugs that offers a short overview of the FDA approval of Vosevi listed above. There is also a comprehensive overview of Vosevi that can be found on our Hep C Medications Blog at http://hepatitiscmedications.hcvadvocate.org/vosevii/. It is also expected that AbbVie’s Maviret will be approved by the FDA in August.
In SnapShots I report on two studies 1) examination of acute kidney disease in a sofosbuvir-based treatment study, and 2) an analysis comparing the adherence of people who inject drugs vs. those who don’t inject drugs.
- Healthwise by Lucinda K. Porter—Life After Hepatitis C-Lucinda provides valuable information about moving on after being cured of hepatitis C and provides opinions from some of the leading experts on liver disease.
- Hepatitis C in Children by Alan Franciscus—I provide an overview of hepatitis C in children including the prevalence, transmission from mother–to-child, testing children, transmission among children, disease progression and monitoring, and treatment with direct-acting antiviral medications.
- Under the Umbrella by Matthew Zielske—Matthew discusses the HCSP Train-the-Trainer workshops he conducts and the concerns that the workshop attendees experience in their daily work trying to combat the opiate epidemic sweeping the country.
- What’s Up!
Check out five new Harm Reduction fact sheets:
Lastly, we found a glitch in our website email system. If you sent an email to us and you never received a response it is likely that it was one of the automatic email systems that was broken. The problem has been fixed and the system is working correctly. If you still need information feel free to email me at alanSCrEWfranciscus@hcvadvocate.org.
In this month’s July HCV Advocate newsletter we have the following articles for your educational and reading pleasure:
- HealthWise: World Hepatitis Day 2017 by Lucinda K. Porter, RN—Lucinda discusses the importance of World Hepatitis Day, the populations it is affecting around the world, and how various organizations are responding to the hepatitis B and C epidemic.
International Liver Conference – Part 3 – Third Time’s the Charm – This is our final coverage in the HCV Advocate newsletter.
- My coverage includes three studies: (1) a study of hepatitis C (HCV) treatment of injection drug users with Epclusa, (2) improvement of glycemic control (diabetes) in people who responded to HCV treatment with sofosbuvir-based therapies, and (3) HCV treatment in people with kidney disease.
- Matthew’s coverage includes 2 studies: (1) the treatment of HCV in post-transplant people coinfected with HIV, and (2) the outcomes of people treated with direct-acting antiviral medications while waitlisted for a liver transplant evaluated one year post-transplant.
- What’s Up!
- We have five new Harm Reduction Fact Sheets:
- Bleach: How to clean a syringe with bleach
- Injection Techniques: Techniques on safe injecting
- Naloxone: What is it and how to use it?
- Opioids: What are they and how they work?
- Vein and Artery Care: How to take care of your veins and arteries, and when to know you hit a vein or artery.
- Alan’s coverage includes: final results from a phase 3 study of glecaprevir plus pibrentasvir (one pill/once-a-day) to treat genotype 3; a phase 2 study of MK-3682/grazoprevir plus ruzasvir to treat people who previously failed direct-acting antiviral therapy; treatment with sofosbuvir/velpatasvir plus voxilaprevir (one-pill, once-a-day) in treatment experienced patients with resistance and finally a study comparing liver cancer outcomes in people achieving a cure with interferon-based therapies vs. direct-acting antiviral therapies.
- Lucinda’s coverage includes: high cure rates with legally imported generic HCV drugs; Harvoni in patients with HCV/HBV coinfection; Harvoni +/– ribavirin treatment in children with chronic hepatitis C and lastly physical activity and cardiorespiratory fitness levels in people living with hepatitis C.
- Matthew’s coverage includes: a study of a viral load point-of-care test that has the potential to improve the HCV treatment cascade and the long-term gender differences in outcomes among people with hepatitis B and hepatitis C.
- The Drug Pipeline is be updated on a monthly basis and is always included with the HCV Advocate Newsletter
- What’s Up! Have you listened to our new voiceovers? We have added voiceovers to some of our most popular Easy C fact sheets – check them out!
- Lucinda’s Highlights from ILC 2017: Marijuana and liver transplant waitlist; expanding age-based testing; health-related quality of life and children treated with sofosbuvir and ribavirin; the effect of cholesterol and low-density lipoprotein after DAA treatment, and cardiovascular and cerebrovascular effects after DAA therapy.
- Alan’s Highlight’s from ILC 2017: Prevalence of concomitant substance abuse and mental health disorders in a HCV treatment program; factors associated with spontaneous viral clearance; treatment of acute HCV in people with HIV; treatment of HCV in New Mexico prison using telemedicine.
- Matthew’s Highlight’s from ILC 2017: Group medical intervention to improve HCV uptake among PWIDs in a primary care setting; 4 weeks of DAA treatment + ribavirin +/- pegylated interferon to treat PWIDs; evaluation of homeless on HCV treatment among PWIDs.
- What’s Up!
- Monday June 5th – Vestavia, Alabama
- Wednesday June 7th –Montgomery, Alabama
We have added a voiceover feature to some of our Easy C Fact Sheets:
What are Ravs / Viral Load Test / Taking HCV Meds / Ribavirin Warning
Hepatitis B Warning / Hepatitis C Antibody Test / Drug Resistance\What is HCV Genotype?
What is ALT? / What is Subtype?
Instructions on how to listen to the voiceovers are included on an overview website page (here). I would be very interested in feedback from our readers on the current voiceovers and recommendations for voiceovers on other fact sheets. Thank You!
- HealthWise – Sleep: The Key to a Healthy Liver by Lucinda K. Porter, RN. In this month’s column Lucinda explores the connection between sleep, the liver, a person’s health and the dreaded daylight saving time.
- SnapShots—by Alan Franciscus. I discuss three studies: Zepatier to treat people with bleeding disorders, the transformation of HCV treatment from the interferon era to direct-acting antiviral era with the VA system and finally the incidence of fatty liver in people with HIV, HCV, HIV/HCV coinfection and those with neither—and the very surprising outcome from the study.
- Under the Umbrella—Five Ways Hepatitis C is Unique to Women by Matthew Zielske. Matthew lays out five important facts about women and hepatitis C that you may or may not know about women infected with hepatitis C.
- What’s Up!
- HealthWise – Why We Need to Treat Everyone Who Has Hepatitis C by Lucinda K. Porter, RN – Lucinda explores how to eliminate hepatitis C in this thought-provoking article.
- Under The Umbrella—The Pros and Cons of Learning about Hepatitis C on the Internet by Matthew Zielske—Matthew writes about the pros and cons of educating ourselves and others about hepatitis C on the internet.
- SnapShots by Alan Franciscus.In this month’s column I write about three studies—the new liver chemistry guidelines issued, potential liver injury from herbal and dietary supplements, and an analysis about the treatment using Zepatier in people with compensated cirrhosis.
- The Drug Pipeline has been pretty quiet this month with the exception of the news that AbbVie’s two drug combination of glecaprevir plus pibrentasvir to treat all genotypes (pan-genotypic) had been granted a FDA priority review-meaning that the drug approval process will be speeded up.
- What’s Up! – In this month notice we have updated the following fact sheets:
- HealthWise – Connecting the Heart and the Liver – Lucinda K. Porter, RN. Lucinda talks about the health of these important organs. The number of people who die from heart disease annually is staggering.
- Under The Umbrella—Harm Reduction and Hepatitis C – Matthew Zielske.Matthew discusses aspects of harm reduction geared towards hepatitis C transmission. He is also working on many new Harm Reduction fact sheets for the HCV Advocate Website. Three new fact sheets are listed below.
- SnapShots – Alan Franciscus. In this month’s column I cover three studies—deaths caused by hepatitis C among Mexican Americans, non-Hispanics Whites and non-Hispanic Blacks, the changes in the most common indications for liver transplants and transplant waitlists and finally, a study that looked at the best practice to screen people at risk (including Baby Boomers) for hepatitis C in an effort to increase screening. All three studies are very illuminating.
- Drug Pipeline — no changes in this month’s Drug Pipeline
- What’s Up! – New this month are three Harm Reduction Fact Sheets:
- Harm Reduction and Alcohol
- Harm Reduction and Indirect Sharing
- Harm Reduction Definitions
- Coming Mid-February: Hepatitis C Drug Pipeline and Conference Coverage – The new feature will be populated by our conference coverage from 2016, from EASL and AASLD, and future conferences as well as current and future articles about drugs in development.
- 2016 In Review: Check out what our staff picked as the top news of last year.
- Under the Umbrella – The Art of Seeing by Matthew Zielske—Matthew discusses the meaning of being an advocate – an inspiring article to bring in 2017
- HealthWise by Lucinda K. Porter RN – Lucinda writes and argues for the elimination of hepatitis C in the United States and globally.
- AASLD 2016 – Part 2 by Alan Franciscus-I write about drugs in development to treat hepatitis C, monitoring people who are at risk for liver cancer and treating hepatitis C in people who inject drugs.
- HCV Advocate Pipeline
- What’s Up!
- Paper PI – we have decided to close down the Paper PI newsletter since we cover all the news in our News and Pipeline Blog.
- HCV and Harm Reduction – we have launched a new series of fact sheets on Harm Reduction. The first piece is an Overview of Harm Reduction by Matthew Zielske.
- Easy C Fact Sheet – Hep C Prevention in a Household – A common concern for people living together. This simple fact sheet provides information on how to stay safe
- Easy C Fact Sheet – Beware of Hepatitis B – we have revised this fact sheet based on feedback. The actual cases of HBV reactivation are uncommon and occurred with pegylated interferon therapies and the new direct-acting antiviral therapies.